基于潜在配体结合位点的HIV整合酶抑制剂对接研究

arXiv: Biomolecules Pub Date : 2012-10-11 DOI:10.5121/ijbb.2012.2303

Subhomoi Borkotoky

{"title":"基于潜在配体结合位点的HIV整合酶抑制剂对接研究","authors":"Subhomoi Borkotoky","doi":"10.5121/ijbb.2012.2303","DOIUrl":null,"url":null,"abstract":"HIV integrase is a 32 kDa protein produced from the C-terminal portion of the Pol gene product, and is an attractive target for new anti-HIV drugs. Integrase is an enzyme produced by a retrovirus (such as HIV) that enables its genetic material to be integrated into the DNA of the infected cell. Raltegravir and Elvitegravir are two important drugs against integrase.","PeriodicalId":8447,"journal":{"name":"arXiv: Biomolecules","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2012-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"Docking Studies on HIV Integrase Inhibitors Based On Potential Ligand Binding Sites\",\"authors\":\"Subhomoi Borkotoky\",\"doi\":\"10.5121/ijbb.2012.2303\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"HIV integrase is a 32 kDa protein produced from the C-terminal portion of the Pol gene product, and is an attractive target for new anti-HIV drugs. Integrase is an enzyme produced by a retrovirus (such as HIV) that enables its genetic material to be integrated into the DNA of the infected cell. Raltegravir and Elvitegravir are two important drugs against integrase.\",\"PeriodicalId\":8447,\"journal\":{\"name\":\"arXiv: Biomolecules\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-10-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"arXiv: Biomolecules\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5121/ijbb.2012.2303\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"arXiv: Biomolecules","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5121/ijbb.2012.2303","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 3

摘要

HIV整合酶是一种由Pol基因c端产物产生的32 kDa蛋白，是一种新的抗HIV药物的有吸引力的靶点。整合酶是逆转录病毒(如HIV)产生的一种酶，它能使其遗传物质整合到受感染细胞的DNA中。雷替格拉韦和依韦替格拉韦是两种重要的抗整合酶药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Docking Studies on HIV Integrase Inhibitors Based On Potential Ligand Binding Sites

HIV integrase is a 32 kDa protein produced from the C-terminal portion of the Pol gene product, and is an attractive target for new anti-HIV drugs. Integrase is an enzyme produced by a retrovirus (such as HIV) that enables its genetic material to be integrated into the DNA of the infected cell. Raltegravir and Elvitegravir are two important drugs against integrase.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

arXiv: Biomolecules

自引率

0.00%

发文量